Social Capital Suvretta Holdings III in an 8-K filing today said it will postpone a vote on the proposed merger with ProKidney while the companies continue to work on satisfying the closing conditions, specifically securing Nasdaq approval of the listing application.
The SPAC expects to reschedule the vote, originally set for today. All shareholders of record as of the close of business on June 2 are entitled to vote.
With an equity value of $2.64 billion, the deal announced in January is expected to deliver up to $825 million to ProKidney, assuming no redemptions. Read more.
